Trevogrumab Curbs Muscle Loss on GLP-1, Aids Regain After
Medscape reports phase 2 COURAGE results, presented at EASD 2026, on trevogrumab, an investigational antimyostatin drug, in 975 patients taking semaglutide. Over 26 weeks, lean mass fell 6.6% with placebo versus 3.4% with trevogrumab 200 mg. During weight regain after semaglutide stopped, lean mass rose more with trevogrumab than placebo. Muscle spasms increased at most doses, and a discussant said functional effects need further study.
Why it matters: Relevant to adults using semaglutide for medical weight loss, and the clinicians who manage them, who are concerned about lean muscle loss during treatment.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to medscape.com. October 8, 2026.